Virginia M. Klimek
Synta Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Cancer Genomics and Diagnostics, Melanoma and MAPK Pathways, Multiple Myeloma Research and Treatments
Most-Cited Works
- → Decitabine improves patient outcomes in myelodysplastic syndromes(2006)1,506 cited
- → The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells(2017)1,300 cited
- → Molecular International Prognostic Scoring System for Myelodysplastic Syndromes(2022)765 cited
- → Cancer therapy shapes the fitness landscape of clonal hematopoiesis(2020)711 cited
- → Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412(2004)660 cited
- → Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes(2020)618 cited
- → Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3(2010)501 cited
- → H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers(2018)500 cited
- → Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q(2007)422 cited
- → Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology(2016)293 cited